Program
Aripiprazole
Also written as “aripiprazole”, “Aripiprazole IM Depot” and “Antidepressant + Aripiprazole”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Tourette Syndrome · Autistic Disorder, led by 10 companies.
Drug pageAripiprazole: every studyMany companies study it; this page follows only the 124 they lead. All 292 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 1120 open or running | phase 4since Mar 26, 2004 | May 7, 2002 | none ahead |
| Johnson & Johnsonits history only | 40 open or running | phase 4since Feb 10, 2012 | Feb 10, 2012 | none ahead |
| Abdi İbrahim Otsukaits history only | 10 open or running | phase 4since Feb 23, 2016 | Feb 23, 2016 | none ahead |
| Chengdu Kanghong Pharmaceutical Groupits history only | 10 open or running | no phasesince Jul 24, 2017 | Jul 24, 2017 | none ahead |
| CMG Pharmaceuticalits history only | 10 open or running | phase 1since Jun 4, 2015 | Jun 4, 2015 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | no phasesince Mar 23, 2026 | Mar 23, 2026 | Sep 5, 2027NCT07547384 |
| Genovate Biotechnologyits history only | 10 open or running | phase 4since Oct 8, 2007 | Oct 8, 2007 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Mar 27, 2023 | Mar 27, 2023 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Aug 18, 2011 | Aug 18, 2011 | none ahead |
| H. Lundbeckits history only | 10 open or running | phase 3since Oct 7, 2013 | Oct 7, 2013 | none ahead |
Also a collaborator on its studies: PRA Health Sciences, Covance and Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Otsuka only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Jan 19, 2008.
- Aug 18, 2014Phase 1 study in SchizophreniaNCT02220712 · 17 enrolled · Japan
- Apr 15, 2015Phase 3 study in SchizophreniaNCT02435836 · 631 enrolled
- Mar 13, 2016Phase 2 study in SchizophreniaNCT02722967 · 49 enrolled · United States
- May 2, 20172 phase 1 studies in SchizophreniaNCT03150771, NCT03287505
- May 11, 2017Phase 3 study in SchizophreniaNCT03172871 · 436 enrolled · China
- Sep 11, 2017Phase 1 study in SchizophreniaNCT03285503 · 12 enrolled · China
- Dec 13, 2017Phase 4 study in SchizophreniaNCT03376763 · 201 enrolled · Korea, Republic of
- Mar 27, 20182 phase 3 studiesNCT03487783, NCT03487770
- May 25, 2018Phase 4 study in SchizophreniaNCT03568500 · 44 enrolled · United Kingdom
- Sep 5, 2018Phase 4 study in Tourette SyndromeNCT03661983 · 36 enrolled · United States, Canada, Hungary
- Feb 12, 2019Phase 1 study in SchizophreniaNCT03854409 · 72 enrolled · United States
- Mar 21, 2019Phase 3 study in SchizophreniaNCT03892889 · 277 enrolled · United States
- Jul 19, 2019Phase 2 study in SchizophreniaNCT04030143 · 266 enrolled · United States
- Mar 29, 2024No phase study in Mental DisordersNCT06372210 · 54 enrolled · United States
TargetBeta
“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brexpiprazolerule | Otsuka | phase 4 | 70 |
Studies
The newest 60 of 112 Otsuka leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06372210Mental Disorders · United States | – | Completed | Jul 19, 2023 | 54 |
| NCT04030143Schizophrenia · United States | 2 | Completed | Jul 8, 2020 | 266 |
| NCT03892889Schizophrenia · United States | 3 | Terminated | Aug 12, 2020 | 277 |
| NCT03854409Schizophrenia · United States | 1 | Completed | Apr 5, 2019 | 72 |
| NCT03661983Tourette Syndrome · United States, Canada, Hungary | 4 | Terminated | Jun 30, 2020 | 36 |
| NCT03568500Schizophrenia · United Kingdom | 4 | Completed | May 21, 2019 | 44 |
| NCT03487783Tourette Syndrome · China | 3 | Completed | Feb 14, 2020 | 121 |
| NCT03487770Autistic Disorder · China | 3 | Completed | Apr 21, 2020 | 111 |
| NCT03376763Schizophrenia · Korea, Republic of | 4 | Completed | Nov 19, 2021 | 201 |
| NCT03285503Schizophrenia · China | 1 | Completed | Oct 14, 2019 | 12 |
| NCT03287505Schizophrenia · China | 1 | Completed | Nov 8, 2019 | 24 |
| NCT03172871Schizophrenia · China | 3 | Completed | Jul 22, 2019 | 436 |
| NCT03150771Schizophrenia · United States | 1 | Completed | Apr 18, 2018 | 36 |
| NCT02722967Schizophrenia · United States | 2 | Completed | Sep 2016 | 49 |
| NCT02435836Schizophrenia | 3 | Terminated | Dec 2012 | 631 |
| NCT02220712Schizophrenia · Japan | 1 | Completed | Apr 2015 | 17 |
| NCT02091882Device Latency · United States | 4 | Completed | Apr 18, 2014 | 30 |
| NCT02054702Schizophrenia | 3 | Completed | Jun 2014 | 97 |
| NCT01981811Schizophrenia · United States | 2 | Withdrawn | May 2014 | 0 |
| NCT01942161Schizophrenia · Japan | 3 | Completed | Nov 2014 | 106 |
| NCT01942148Schizophrenia · Japan | 3 | Completed | Nov 2015 | 68 |
| NCT01909466Schizophrenia · United States | 1 | Completed | Mar 2014 | 141 |
| NCT01870999Schizophrenia · United States | 1 | Completed | Oct 2008 | 41 |
| NCT01727713Tourette Syndrome · United States, Canada, Hungary and more | 3 | Completed | Aug 2014 | 110 |
| NCT01727700Tourette Syndrome · United States, Canada, Germany and more | 3 | Completed | Aug 2013 | 133 |
| NCT01710709Bipolar I · United States, Canada, France and more | 3 | Completed | Nov 2016 | 748 |
| NCT01683058Schizophrenia · United States, Croatia, Latvia | 3 | Completed | Feb 2014 | 74 |
| NCT01663532Schizophrenia · United States, Croatia, Latvia | 3 | Completed | Aug 2013 | 340 |
| NCT01646827Schizophrenia · United States | 1 | Completed | Apr 2013 | 37 |
| NCT01617460Autistic Disorder · Japan | 3 | Completed | Oct 2016 | 86 |
| NCT01617447Autistic Disorder · Japan | 3 | Completed | Jun 2015 | 92 |
| NCT01552772Schizophrenia · United States | 1 | Completed | Apr 2012 | 60 |
| NCT01509053Schizophrenia · Belgium, Bulgaria, Canada | 3 | Terminated | Oct 2012 | 30 |
| NCT01432444Schizophrenia · United States, Canada | 3 | Completed | Dec 2013 | 493 |
| NCT01438060Alzheimer Disease | 3 | Completed | Jul 2010 | 232 |
| NCT01429831Depressive Disorder, Major · Taiwan | 4 | Completed | May 2013 | 300 |
| NCT01418352Tourette Syndrome · United States, Bulgaria, Germany and more | 3 | Completed | Mar 12, 2014 | 83 |
| NCT01418339Tourette Syndrome · United States, Canada, Hungary and more | 3 | Completed | Nov 6, 2013 | 135 |
| NCT01416441Tourette Syndrome · United States, Bulgaria, Canada and more | 3 | Completed | Mar 13, 2014 | 170 |
| NCT01227668Irritability Associated With Autistic Disorder · United States | 4 | Completed | Jun 20, 2012 | 215 |
| NCT01149655Schizophrenia · United States, India, Malaysia and more | 3 | Completed | Nov 2013 | 252 |
| NCT01129882Schizophrenia · United States, Argentina, Australia and more | 3 | Completed | Dec 6, 2018 | 709 |
| NCT01123707Depressive Disorder, Major | 3 | Terminated | Sep 27, 2011 | 173 |
| NCT01122927Mania · United States, Bulgaria, Croatia and more | 3 | Terminated | Aug 2014 | 524 |
| NCT01111565Depressive Disorder, Major · United States, Canada, Croatia and more | 3 | Terminated | Sep 1, 2011 | 137 |
| NCT01111552Depressive Disorder, Major · United States, Australia, Bulgaria and more | 3 | Terminated | Sep 27, 2011 | 237 |
| NCT01111539Depressive Disorder, Major · United States, Estonia, Finland and more | 3 | Terminated | Sep 20, 2011 | 211 |
| NCT01001702Schizophrenia · Argentina, Croatia, India and more | 3 | Completed | Jul 2012 | 85 |
| NCT00882362Depressive Disorder, Major · Japan | 3 | Completed | Jul 2012 | 155 |
| NCT00876343Depressive Disorder, Major · Japan | 3 | Completed | Jul 2012 | 586 |
| NCT00857818Schizophrenia · Canada | 3 | Terminated | Mar 2010 | 64 |
| NCT00731549Schizophrenia · United States, Argentina, Australia and more | 3 | Completed | Nov 2013 | 1,081 |
| NCT00712686Schizophrenia | 3 | Completed | Dec 2003 | 690 |
| NCT00706654Schizophrenia · United States, Austria, Belgium and more | 3 | Completed | Aug 1, 2012 | 937 |
| NCT00706589Tic Disorders · Korea, Republic of | 3 | Completed | Apr 2010 | 61 |
| NCT00705783Schizophrenia · United States, Argentina, Bulgaria and more | 3 | Completed | Aug 2010 | 843 |
| NCT00665366Bipolar Disorder Mania · Austria, Czech Republic, France and more | 3 | Completed | Oct 2011 | 493 |
| NCT00606320Bipolar I Disorder · China, Japan, Korea, Republic of and more | 3 | Completed | Nov 2010 | 59 |
| NCT00606281Bipolar I Disorder · China, Japan, Korea, Republic of and more | 3 | Completed | Nov 2010 | 258 |
| NCT00606229Bipolar I Disorder · Japan | 3 | Completed | Nov 2010 | 41 |
How it is read
Names in the registry
- “Aripiprazole”, 81 entries
- “aripiprazole”, 13 entries
- “Aripiprazole IM Depot”, 7 entries
- “Antidepressant + Aripiprazole”, 2 entries
- “Aripiprazole for Injection”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 63 studies
- Bipolar Disorder, 15 studies
- Depressive Disorder, Major, 10 studies
- Tourette Syndrome, 8 studies
- Autistic Disorder, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.